The Toxic Effect and Mechanism of TMZ Combined with siHOXB9 on Glioblastoma Cells.

Xiaoyu Liu, Yunfei Liu, Wenxuan Li, Qianwen Wang, Ziyu Huang, Xiyu Cheng, Qiong Yan, Honggang Hu

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoyu LiuDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.

Yunfei LiuDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.ORCID 0009-0005-8328-3281

Wenxuan LiDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.

Qianwen WangDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.ORCID 0009-0009-4438-3684

Ziyu HuangDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.

Xiyu ChengDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.ORCID 0000-0003-1086-7620

Qiong YanDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.

Honggang HuDepartment of Physical Science and Engineering, Beijing Jiaotong University, Beijing 100091, China.

Funding

Beijing Natural Science Foundation 7232101

6 · The paper itself

Abstract

Glioblastoma (GBM) represents a highly invasive primary malignant tumor within the central nervous system (CNS). Temozolomide (TMZ), a first-line chemotherapy agent for GBM treatment, has significant limitations, including drug resistance, poor water solubility, a short half-life, and notable toxic side effects. The innovation of the TMZ dosage form is pivotal for enhancing its therapeutic efficacy. In this study, solid lipid nanoparticles (SLN) loaded with Angiopep-2 (A2) and TMZ (TMZ-A2SLN), a nanopolymer featuring a solid spherical morphology and a particle size of approximately 100 nm, were constructed. The combined effect of TMZ-A2SLN and small-interfering RNA (siRNA) that can knock down the expression of the

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsGlioblastomaHomeodomain ProteinsRNA, Small InterferingTemozolomideApoptosisCell Line, TumorCell SurvivalHumansLiposomesNanoparticlesAntineoplastic Agents, AlkylatingHomeodomain ProteinsLipid NanoparticlesLiposomesRNA, Small InterferingTemozolomideglioblastomaproteomicssolid lipid nanoparticletemozolomideU251 cell

Identifiers

PMID41515958

DOI10.3390/ijms27010079

PMCPMC12785943

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.